<DOC>
	<DOC>NCT02247804</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.</brief_summary>
	<brief_title>Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<criteria>Diagnosis of either openangle glaucoma or ocular hypertension in each eye and both eyes require IOPlowering treatment. Previous enrollment in Allergan Study 192024041D Eye surgery (including cataract surgery) and/or any eye laser surgery within the past 6 months in the study eye Anticipated need for laser eye surgery in either eye within the first 52 weeks of the study duration History of glaucoma surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>